Rep. Lisa C. McClain Sells Repligen Corporation (NASDAQ:RGEN) Stock

Representative Lisa C. McClain (R-Michigan) sold shares of Repligen Corporation (NASDAQ:RGEN) worth between $1,001 and $15,000 on October 30th. The transaction was disclosed on November 21st. Repligen's stock traded up 2.2% to $171.00. The company reported $0.46 earnings per share for the last quarter, beating estimates. Several large investors have adjusted their stakes in Repligen. Analysts have mixed ratings on the stock.

Representative Lisa C. McClain (R-Michigan) recently sold shares of Repligen Corporation NASDAQ: RGEN. In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in Repligen stock on October 30th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Why Medical Products Maker Repligen May Be A Potential Buy

Representative Lisa C. McClain also recently made the following trade(s):

Sold $1,001 - $15,000 in shares of Ciena NYSE: CIEN on 10/31/2025.
Sold $1,001 - $15,000 in shares of Alibaba Group NYSE: BABA on 10/31/2025.
Sold $1,001 - $15,000 in shares of Coherent NYSE: COHR on 10/31/2025.
Sold $1,001 - $15,000 in shares of Clorox NYSE: CLX on 10/31/2025.
Sold $1,001 - $15,000 in shares of Northern Trust NASDAQ: NTRS on 10/31/2025.
Sold $1,001 - $15,000 in shares of Honda Motor NYSE: HMC on 10/31/2025.
Sold $1,001 - $15,000 in shares of Home BancShares NYSE: HOMB on 10/31/2025.
Sold $1,001 - $15,000 in shares of Five Below NASDAQ: FIVE on 10/31/2025.
Sold $1,001 - $15,000 in shares of Pure Storage NYSE: PSTG on 10/31/2025.
Sold $1,001 - $15,000 in shares of BHP Group NYSE: BHP on 10/31/2025.

Repligen Trading Up 2.2%

NASDAQ:RGEN traded up $3.74 during mid-day trading on Tuesday, hitting $171.00. 482,061 shares of the stock traded hands, compared to its average volume of 823,018. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 52 week low of $102.96 and a 52 week high of $182.52. The firm's 50 day moving average is $145.73 and its two-hundred day moving average is $130.61. The stock has a market capitalization of $9.63 billion, a price-to-earnings ratio of 8,599.55, a PEG ratio of 3.32 and a beta of 1.15.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts' consensus estimates of $0.42 by $0.04. The business had revenue of $188.81 million for the quarter, compared to analyst estimates of $181.23 million. Repligen had a return on equity of 4.70% and a net margin of 0.25%.The company's revenue was up 21.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.43 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. On average, equities research analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC bought a new stake in Repligen during the third quarter worth $29,000. Twin Tree Management LP bought a new position in Repligen during the 1st quarter worth $29,000. Hantz Financial Services Inc. raised its stake in Repligen by 2,663.6% in the second quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 293 shares in the last quarter. Signaturefd LLC boosted its position in shares of Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 128 shares in the last quarter. Finally, CWM LLC increased its stake in shares of Repligen by 67.2% in the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company's stock valued at $45,000 after purchasing an additional 135 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Ratings Changes

A number of analysts have commented on the company. HC Wainwright reiterated a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Wednesday, September 3rd. HSBC started coverage on Repligen in a report on Wednesday, October 1st. They issued a "buy" rating and a $150.00 price objective for the company. Royal Bank Of Canada reissued an "outperform" rating and set a $205.00 target price on shares of Repligen in a research note on Tuesday, September 2nd. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Repligen in a research report on Wednesday, November 19th. Finally, Canaccord Genuity Group increased their price objective on Repligen from $150.00 to $165.00 and gave the stock a "hold" rating in a report on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $173.85.

Check Out Our Latest Analysis on Repligen

Insider Buying and Selling

In other Repligen news, COO James Bylund sold 2,191 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the completion of the transaction, the chief operating officer directly owned 21,520 shares in the company, valued at approximately $3,254,039.20. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Anthony Hunt sold 20,000 shares of the company's stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $154.61, for a total transaction of $3,092,200.00. Following the completion of the transaction, the director owned 80,743 shares of the company's stock, valued at approximately $12,483,675.23. This trade represents a 19.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 49,382 shares of company stock worth $7,676,802 in the last 90 days. Company insiders own 1.20% of the company's stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About Repligen

(Get Free Report)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

Five stocks we like better than Repligen
Unveiling The Power Of VWAP: A Key Indicator For Traders
Missed the AI Boom? These 2 Crushed Stocks Could Be Your Second Chance
3 Monster Growth Stocks to Buy Now
A New Leader at Six Flags: Is the Roller Coaster Over?
How to find penny stocks to invest and trade
3 Reasons Baidu Could Be the Dark Horse of Global AI

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Repligen Right Now?

Before you consider Repligen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.

While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here